Mangalam Drugs
MANGALAM • Pharmaceuticals & Biotechnology
Last Price
₹28.20
Market Cap
₹44.64 Cr
Sector
Pharmaceuticals & Biotechnology
For educational/research use only. Not a recommendation to buy or sell.
At a glance
as of 2026-10-26Sector: Mangalam Drugs (MANGALAM) is an NSE-listed company in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry. NSE sector rotation chart
Sharia rating: Mangalam Drugs is rated Not halal by a specialist third-party provider. Full list of halal NSE stocks
60% below its 52-week high
Price trend
Neutral
Over the last 6 months, Mangalam Drugs's share price has fallen, doing better than 36% of Pharmaceuticals & Biotechnology stocks.
Institutional activity
Positive
Trading patterns over recent weeks show some signs of institutions buying Mangalam Drugs (buying score 4/10, selling score 1/10).
Model rank
Positive
Our model's 5-day return score puts Mangalam Drugs ahead of 69% of NSE stocks. The model has low confidence in this score (37%).
Ease of trading
Elevated
Some signs that trading in Mangalam Drugs is thinner than usual (risk score 4/10). Volume has been below normal for 9 days.
Price vs profits
Loss-making
Mangalam Drugs did not make a profit last year, so there is no profit to compare the price against.
The wider Indian market is in a crisis regime — unusually sharp moves (model 100% sure). This affects every stock's model rank.
Browse ready-made screens →Company Information
About Mangalam Drugs (MANGALAM)
Mangalam Drugs is an NSE-listed company operating in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry (ISIN INE584F01014). This page brings together the quantitative research signals our models compute for MANGALAM: a model-estimated 1-day, 5-day and 21-day return outlook, momentum and trend indicators, institutional-activity context derived from observed trading flows, a snapshot of valuation and quality fundamentals, and the instrument's Sharia-compliance status. All figures are produced by statistical models from historical data and are intended for research and educational purposes.
To read the page, treat the model-estimated return outlook as a relative ranking signal rather than a forecast of price — higher scores reflect stronger model-estimated momentum and trend alignment, not a target or guarantee. The momentum and trend indicators describe how Mangalam Drugs's recent price action compares with its own history, while the fundamentals and institutional-activity context add longer-horizon and flow-based perspective. Nothing here is investment advice, a recommendation, or a solicitation to transact; always do your own research and consult a SEBI-registered adviser before making any decision.
The "typical range" we compare a price-to-earnings multiple against is a fixed band for all NSE stocks, not a sector-specific one. Everything on this page describes what our models measured; none of it is a recommendation to do anything.